Engineering CAR T Cells to Eliminate Problems

]]>(MedPage Today) -- A novel anti-CD19 CAR T-cell therapy attained a high response rate with minimal neurotoxicity in patients with advanced B-cell lymphoma, according to a preliminary clinical trial.The results showed that 11 of 20 patients attained...